Company Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.
The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.
Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Country | United States |
IPO Date | Mar 29, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 54 |
CEO | Pratik Shah Ph.D. |
Contact Details
Address: 6005 Hidden Valley Road Carlsbad, California United States | |
Website | https://www.designtx.com |
Stock Details
Ticker Symbol | DSGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001807120 |
CUSIP Number | 25056L103 |
ISIN Number | US25056L1035 |
Employer ID | 82-3929248 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Pratik Shah Ph.D. | Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson |
Dr. Sean Jeffries Ph.D. | Chief Operating Officer |
Dawn Giangiulio | Controller |
Dr. Aseem Z. Ansari Ph.D. | Co-Founder & Scientific Advisor |
Dr. Jae B. Kim FACC, M.D. | Consulting Chief Medical Officer |
Julie D. Burgess CPA | Chief Accounting Officer |
Mustapha Parekh | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 07, 2024 | 10-Q | Quarterly Report |
Nov 07, 2024 | 8-K | Current Report |
Aug 13, 2024 | SC 13D/A | [Amend] Filing |
Aug 12, 2024 | 4 | Filing |
Aug 05, 2024 | 10-Q | Quarterly Report |
Aug 05, 2024 | 8-K | Current Report |
Jun 17, 2024 | 4 | Filing |
Jun 17, 2024 | 4 | Filing |
Jun 17, 2024 | 4 | Filing |
Jun 17, 2024 | 4 | Filing |